Pharmacotherapies available for treating psychiatric illnesses are numerous but suboptimal response and adverse reactions to these therapies are typical and thought to in part a result of genetic variation. Understanding and translating interactions between genetic variation and pharmacotherapy outcomes is a major component of the precision psychiatry approach. The precision psychiatry approach aims to tailor treatment based on an individual’s genomic, phenotypic, and environmental context and holds great promise for psychiatry practice where pharmacotherapy is more or less delivered on a trial-and-error basis.
In this Research Topic, we will cover new developments in the emerging field of psychiatric pharmacogenetics ranging from basic research to translational studies. We welcome original research, reviews, case studies, opinions and perspectives related to any one or more of the following themes.
(a) pharmacokinetic and/or pharmacodynamic mechanisms of psychiatric medications
(b) genetic/genomic markers of psychiatric medication response and/or adverse events
(c) gene-environment markers of psychiatric medication response and/or adverse events
(d) pharmacogenetic-based decision support tools
(e) current state and future of pharmacogenetics in psychiatry
Topic editor Lisa Brown is employed by company Assurex Health Inc. a subsidiary of Myriad Genetics. Topic editor Harris Eyre is employed by company CNSDose psychiatric pharmacogenetics company and BasePair Genomics. Topic editor Josiah Allen is employed by company Medigenics Consulting. All other topic editors declare no competing interests with regards to the Research Topic subject.
Pharmacotherapies available for treating psychiatric illnesses are numerous but suboptimal response and adverse reactions to these therapies are typical and thought to in part a result of genetic variation. Understanding and translating interactions between genetic variation and pharmacotherapy outcomes is a major component of the precision psychiatry approach. The precision psychiatry approach aims to tailor treatment based on an individual’s genomic, phenotypic, and environmental context and holds great promise for psychiatry practice where pharmacotherapy is more or less delivered on a trial-and-error basis.
In this Research Topic, we will cover new developments in the emerging field of psychiatric pharmacogenetics ranging from basic research to translational studies. We welcome original research, reviews, case studies, opinions and perspectives related to any one or more of the following themes.
(a) pharmacokinetic and/or pharmacodynamic mechanisms of psychiatric medications
(b) genetic/genomic markers of psychiatric medication response and/or adverse events
(c) gene-environment markers of psychiatric medication response and/or adverse events
(d) pharmacogenetic-based decision support tools
(e) current state and future of pharmacogenetics in psychiatry
Topic editor Lisa Brown is employed by company Assurex Health Inc. a subsidiary of Myriad Genetics. Topic editor Harris Eyre is employed by company CNSDose psychiatric pharmacogenetics company and BasePair Genomics. Topic editor Josiah Allen is employed by company Medigenics Consulting. All other topic editors declare no competing interests with regards to the Research Topic subject.
